Introduction: Beta blockers have proven benefit in the treatment of chronic heart failure. In CIBIS II, the total mortality and the risk of sudden death were reduced in patients treated with Bisoprolol compared to placebo respectively 11.8% vs. 17.3%, p <0001 and 3.6 vs 6.3%, p < 002 regardless of age, NYHA class and co-morbidities. In our study a similar effect of Bisoprolol in chronic heart failure with right ventricular dysfunction is proposed. Aims: Part of over 80-year-old heart failure (HF) patients is increasing. These patients are poorly studied. The present study undertook a 'real-life' analysis of various aspects of the prognosis of over 80-year-old HF patients in France.
Material and methods:
This study examined the short-term effect of Bisoprolol on right ventricular function in patients with chronic heart failure with right ventricular dysfunction. A cohort of 60 patients with chronic heart failure with right ventricular dysfunction who were not taking beta-blockers has been previously studied prospectively. The RVEF and LVEF were measured at baseline and followed for 6 months by Doppler echocardiography. Various parameters of the right ventricular function were measured: RVEF, fractional shortening surface, TAPS, Doppler tissue S'DTI tricuspid ring and RV Tei index. The significance level was set at 5%. The maximum dose of Bisoprolol was titrated during four monthly visits by a preestablished protocol to a target dose of 10mg / day.
Results:
The average age of participants was 65.7±16.3 years, RVEF at 6 months was 25.6±5.2 and the baseline was 20.8±6.4. The maximum dose of Bisoprolol was 5.7±3.7mg / day. At 6 months the RVEF increased significantly from 7.9% (confidence interval 95%, 03-10.02%, p <0.0001) and left ventricular ejection fraction also increased significantly from 7.5% (range 95% confidence, 4.0-11.9%, p <0.0003). All parameters of right ventricular function were significantly improved.
Conclusion: Treatment with Bisoprolol in chronic heart failure with right ventricular dysfunction at 6 months resulted in a significant improvement in right ventricular ejection fraction, which in parallel with the improvement of left ventricular ejection fraction.
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Use of an intraaortic balloon counter-pulsation as a means of preventing pulmonary edema in patients with laminar flow under peripheral venous-arterial extra-corporeal life support
Pierre Demondion (1), Nicolas Bréchot (2), Guillaume Lebreton (1), Charles Edouard Luyt (2), Jean Louis Trouillet (2), Ania Nieszkowska (2), Jean Chastre (2), Alain Combes (2), Pascal Leprince (1) (1) CHU La Pitié-Salpétrière-APHP, Chirurgie cardiaque, Paris, France -(2) CHU La Pitié-Salpétrière-APHP, Réanimation médicale, Paris, France ExtraCorporeal Life Support (ECLS) restores hemodynamic stability in patients with severe cardiocirculatory failure. However, this circulatory assistance technique has its limits, and the most strongly feared is left ventricular distention, of which the potentially serious consequences range from acute pulmonary edema (APE) to left intraventricular thrombosis. Our hypothesis is that in patients in refractory cardiogenic shock and with laminar flow under peripheral V-A ECLS, IABP use could help to diminish the incidence of acute pulmonary edema (APE).
Methods:
The clinical evolution of patients with laminar flow under peripheral V-A ECLS who did not receive IABP (group A) has been compared to the clinical evolution of patients who received IABP as a means of APE prevention under peripheral V-A ECLS, while also being subjected to laminar flow under peripheral V-A ECLS (group B). A logistic regression model was used to identify the factors associated with occurrence of severe and symptomatic APE.
Results: Between December 2007 and 2012, 90 patients were subjected to laminar flow under peripheral V-A ECLS that had been implanted subsequent to cardiogenic shock. Mortality and mechanical ventilation duration was not significantly different in either of the two groups. However, clinical APE occurrence was far less frequent in group B (35.1% vs. 88.6% p<0.0001). Study of the radiologic score showed that pulmonary infiltrate was greater in group A (p≤0,001). Centralized pulmonary edema was likewise more frequent in group A (44.6% vs. 5.9%, p<0.0001). Multivariate analysis showed that the non-association of IABP with peripheral V-A ECLS (Odds Ratio [OR]=18.87) was an independent factor associated with the incidence of severe symptomatic APE.
Conclusion:
Association of IABP and peripheral V-A ECLS can be considered therapeutically efficient in prevention of severe symptomatic pulmonary edema under peripheral V-A ECLS, even though confirmation would require a randomized study.
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